The APAS Independence is an innovative in vitro diagnostic instrument using artificial intelligence for automated imaging, analysis and interpretation of agar culture plates in microbiology laboratories.

I've taken an intial smallish postion and will continue to add on further good news.

Certainly a high risk proposition however LBT have come a long way over the past few years and have somewhat derisked the business whereby they now hold CE and US FDA approval.

LBT received FDA 510(k) clearance from the United States Food and Drug Administration.

LBT now believe their cash balance of $10.2m at 30 June 2019, makes them well funded into 2021.”

1st mover advantage.

Using AI for continuous improvement.

Capital sales combined with a SaaS provides multiple revenue streams.